MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1136/heartjnl-2017-311430

Медицинская библиотека · Heart (British Cardiac Society) · 2017

Implantable cardiac defibrillator and mortality in non-ischaemic cardiomyopathy: an updated meta-analysis.

Alba Ana C, Foroutan Farid, Duero Posada Juan, Battioni Luciano, Schofield Toni, Alhussein Mosaad, Agoritsas Thomas, Spencer Frederick A, Guyatt Gordon

СтатьяМетаанализСистематический обзорПеревод в очереди

Аннотация

OBJECTIVES

The benefit of implantable cardiac defibrillator (ICD) in symptomatic patients with systolic dysfunction and non-ischaemic cardiomyopathy remains controversial. We conducted a systematic review and meta-analysis to determine the effect of ICD in patients with non-ischaemic cardiomyopathy on (1) all-cause mortality, (2) cardiovascular mortality and (3) sudden cardiac death.

METHODS

We searched citations in meta-analyses published until 2012, and in MEDLINE, Embase, PubMed and Cochrane databases from 2012 to October 2016. We included randomised controlled trials (RCTs) evaluating the effect of ICD therapy on all-cause and cardiovascular mortality and sudden cardiac death in patients with non-ischaemic cardiomyopathy. Independent reviewers evaluated study eligibility, abstracted data and assessed risk of bias in duplicate. We used random-effect models to meta-analyse relative risks (RR) and hazard ratios (HR) across studies, the Grades of Recommendation, Assessment, Development, and Evaluation system to quantify absolute effects and quality of evidence, and I2 to evaluate heterogeneity.

RESULTS

We identified six RCTs including 1715 patients experiencing 421 deaths. ICD therapy was associated with reduced overall mortality (HR 0.78, 95% CI 0.66 to 0.92, I2 = 0%, risk difference 4.7%, high quality), cardiovascular mortality (RR 0.77, 95% CI 0.60 to 0.98, I2 = 39%, risk difference 3.3%, high quality) and sudden cardiac death (RR 0.45, 95% CI 0.29 to 0.70, I2 = 0%, risk difference 4.1%, high quality). The benefit of ICD was not influenced by the use of amiodarone in the comparison group, the duration of follow-up, by use of β-blockers and ACE inhibitors/angiotensin receptor blocker or cardiac resynchronisation therapy.

CONCLUSION

Primary prevention ICD therapy reduces all-cause and cardiovascular mortality and sudden cardiac death in patients with non-ischaemic cardiomyopathy.

Для цитирования: Alba Ana C, Foroutan Farid, Duero Posada Juan, Battioni Luciano, Schofield Toni, Alhussein Mosaad, Agoritsas Thomas, Spencer Frederick A, Guyatt Gordon. Implantable cardiac defibrillator and mortality in non-ischaemic cardiomyopathy: an updated meta-analysis.. Heart (British Cardiac Society). 2017. DOI: 10.1136/heartjnl-2017-311430.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.